AABB Updates Standards for Blood Banks and Transfusion Services
The AABB is implementing changes to the 35th edition of its "Standards for Blood Banks and Transfusion Services." The updates are expected to raise the bar for process validation and analytical rigor in areas relevant to cell and gene therapy manufacturing.
- While the headline refers to standards for blood banks, the more pertinent guidelines for a gene therapy CDMO are AABB's "Standards for Cellular Therapy Services," with the 12th edition effective as of July 1, 2025. These standards are built on a "Quality Systems Essentials" framework that emphasizes error prevention over detection, a principle that extends to all manufacturing and data systems. - The standards mandate validation for all processes and procedures, which for automated viral vector manufacturing, necessitates a systematic approach to provide documented evidence that the process consistently meets predefined quality standards. This includes not just the performance qualification of individual automated units but also the validation of the entire integrated workflow to ensure process robustness and reproducibility. - For digital systems, the standards require defined processes for monitoring the integrity of critical data elements and validation of information system software, hardware, and databases before implementation. This has direct implications for LIMS and electronic batch record systems, requiring robust audit trails, access controls, and verified data accuracy from the point of entry to final disposition. - The AABB standards' emphasis on traceability, requiring that equipment be uniquely identified and that any product can be traced to all associated equipment, informs the data architecture for biomanufacturing. This necessitates a data infrastructure that can seamlessly link process data from various automated systems and analytical instruments to the specific batch and patient, ensuring a complete and auditable record. - A key collaboration to note is the AABB/ISCT GTP Interpretative Tool, developed to help the cell therapy community understand and implement Good Tissue Practice (GTP) requirements and prepare for FDA inspections. This resource provides guidance on regulatory pathways for cell and tissue-based products. - AABB has also introduced specific "Cell and Gene Therapy Standards for Pharmacy," which, while focused on the dispensing side, signal a move toward more specific guidance for the entire CGT product lifecycle. These standards address the unique storage, handling, and chain of identity requirements for these complex therapies.
